It does seem very odd that they would refuse it. ARNA does not meet their efficacy requirements, is an unknown drug, and has some questionably possible problems like addiction, heart and cancer questions. That would mean that either the EU is not concerned about ARNA's issues, or that they are not interested in approving either drug.
It really is surprising that they have taken a stand against Qsymia. It works well, and it's side effects are well documented and avoidable. I am very curious what their reasons are.
I reread the voting procedures and basically I do not see a chance of approval this go round and completely rule it out.
from the emea procedures:
"Where a trend vote has been recorded and notified to the applicant /MAH, it is not anticipated that the final formal vote will reflect a change in the opinion of the Committee, unless anything has changed substantially from the time of the trend vote to that of the final vote."
We'll get from the minutes though who didn't do their homework:
"The outcome of the voting, including the number of positive and negative votes in the event of a split opinion, as well as the names of any members expressing a divergent view, will be recorded in both the Minutes of the meeting and in the final opinion."
Also, it requires majority vote for approval so that means 51% of voters did not approve so a single country cannot close us out(france). VVUS has work to do. A better prepared EU company may have gotten it through IMO. 51% failure is pathetic for a drug that received approval in the US.